MKMustafa Kılıç

Mustafa Kılıç

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Mustafa Kılıç has a total of 326 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Clinical spectrum and genetic landscape of MTHFR deficiency: a cohort study including novel variants

    by Karalar Pekuz, Ozge Kamer, Pelin Teke Kisa, Sevil Yildiz, Mehmet Kocabey, Tanyel Zubarioglu, Zumrut Arslan Gulten, Emine Sedef Sezen, Esra Er, Serdar Pekuz, et al.

  • İzole sülfit oksidaz eksikliği: SUOX geninde homozigot p.Gly362Ser varyantı saptanan 10 aylık bir olgu

    by Sevgi Doğan, Gizem Gökçe Altaş, Sümeyya Duran Kaymak, Mustafa Kılıç

    İzole sülfit oksidaz eksikliği, SUOX genindeki bialelik patojenik varyantlara bağlı gelişen, ağır nörolojik tutulumla seyreden nadir bir nörometabolik hastalıktır. On aylık erkek hasta, mikrosefali, epilepsi, serebral palsi ve kardeş ölüm öyküsü nedeniyle metabolik açıdan değerlendirildi. Fizik muayenesinde gelişim geriliği, aksiyel hipotoni ve periferik spastisite saptandı. Beyin manyetik rezonans görüntülemesinde yaygın serebral atrofi, korpus kallozum agenezisi, ventrikülomegali ve periventriküler kistik değişiklikler izlendi. Klinik ekzom dizilemesinde SUOX geninde homozigot c.1084G>A (p.Gly362Ser) patojenik varyant gösterilerek izole sülfit oksidaz eksikliği tanısı doğrulandı. Ayrıca literatürde bildirilen Türk kökenli olgular klinik, radyolojik ve genetik özellikleri açısından gözden geçirildi. Erken başlangıçlı nöbetler, ilerleyici ensefalopati ve karakteristik nörogörüntüleme bulguları bulunan hastalarda izole sülfit oksidaz eksikliği ayırıcı tanıda düşünülmeli ve erken moleküler genetik inceleme yapılmalıdır.

  • Open Access

    Infection-triggered neurological deterioration and immunodeficiency in a case of RNU4ATAC-opathy

    by Deniz Yaşar, Mustafa Kılıç, Abdülkerim Kolkıran, Ayşe Kaçar Bayram, Özlem Sarıtaş Nakip, Berna Uçan, Hüsniye Yücel, Elif Soyak Aytekin

    Introduction. RNU4ATAC-opathy is a rare autosomal recessive disorder characterized by a wide clinical spectrum, including brain anomalies, seizures, strokes, immunodeficiency, and cardiac defects. Other manifestations include ophthalmologic, dermatologic, renal, gastrointestinal, auditory, and endocrine involvement. Here, we report the identification of pathogenic RNU4ATAC variants through whole exome sequencing in an infant presenting with microcephaly, growth failure, and immunodeficiency. Case Presentation. We describe an 11-month-old infant who had been followed since 4 months of age for growth failure and developmental delay. During follow-up, the patient experienced episodes of neurological deterioration triggered by febrile illnesses associated with SARS-CoV-2 and respiratory syncytial virus infections (RSV) at 9 and 11 months of age, respectively. Immunological evaluation showed normal immunoglobulin levels, a marked reduction in switched memory and memory B cells, impaired T-cell activation, and decreased T-cell subpopulations, suggesting combined immunodeficiency that may have contributed to increased susceptibility to viral infections. Whole exome sequencing subsequently identified compound heterozygous pathogenic variants in the RNU4ATAC gene, confirming the diagnosis of RNU4ATAC-opathy. Discussion. RNU4ATAC-opathy should be considered in cases with microcephaly, growth failure, immunodeficiency, and skeletal abnormalities. Our case shows that RNU4ATAC-opathy may present as infection-related encephalopathy, together with combined T- and B-cell dysfunction. Early immunological assessment and timely initiation of prophylactic therapy could play a key role in improving survival. Genetic and immunological evaluations are essential for accurate diagnosis, early intervention, and effective management. Further research is needed to clarify the syndrome’s impact on immune function and guide targeted therapies.

  • Open Access

    Phenotypic spectrum in patients with 16p11.2 deletion: a single tertiary centre experience in Türkiye

    by Ahmet Kablan, Abdüllatif Bakır, Elifcan Taşdelen, Firdevs Dinçsoy Bir, Abdulkerim Kolkıran, Melike Ataseven Kulalı, Ergin Atasoy, Deniz Menderes, Ayşegül Efe, Mustafa Kılıç, et al.

    Background. The 16p11.2 deletion is one of the most frequent recurrent copy number variations associated with a broad neurodevelopmental and phenotypic spectrum. Despite its relatively well-characterized genomic region, clinical expressivity remains highly variable, posing challenges for diagnosis and management. Methods. We conducted a retrospective single-centre study of 25 individuals with molecularly confirmed 16p11.2 deletions, including 13 males (52%), 12 females (48%), and 7 familial (28%). Both de novo and inherited cases were included. The main testing method was chromosomal microarray, although karyotyping and additional tests such as sequencing and trinucleotide repeat testing were also utilized. Comprehensive clinical data were collected from medical records, including neurodevelopmental, neuropsychiatric, metabolic, skeletal, and systemic features. Results. The majority of the cases had the typical ~600 kilobase deletion while two had distal ~220kb deletion. One patient was found to have a double genetic diagnosis. Developmental delay was almost universal in the probands, with expressive language significantly more impaired than receptive language abilities. Intellectual disability / learning difficulties and language problems were observed in 18/25 (72%) cases. Around half of the probands showed obesity and related hyperphagia. Autism spectrum disorder, attention deficit hyperactivity disorder, stereotypic movements, and aggressive behaviour were frequently reported. Epilepsy was present in thirteen patients (52%), with electroencephalographic abnormalities supporting generalized or focal epileptiform activity. Dysmorphic facial features and skeletal anomalies such as pes equinovarus, syndactyly, and scoliosis were variably present. Brain magnetic resonance imaging revealed abnormalities in several patients, including hypoplasia of the corpus callosum and intracranial hypertension. Additional systemic findings included hepatic steatosis, constipation, and ophthalmologic anomalies. Parental testing revealed asymptomatic or mildly affected carriers in multiple cases. Conclusion. Our findings emphasize the broad and heterogeneous clinical spectrum of 16p11.2 deletions in a Turkish cohort. Early recognition, multidisciplinary evaluation, and family-based genetic counselling are essential for timely diagnosis and optimal care of affected individuals.

  • Atypical Biallelic Inheritance in “Dominant” Genes: Evidence From a Large‐Scale Consanguineus Exome Cohort

    by Elifcan Taşdelen, Umut Can Tekbaş, Abdulkerim Kolkıran, Semra Çetinkaya, Mustafa Kılıç, Abdullah Sezer

    Exome sequencing (ES) has improved Mendelian disease diagnosis, but in consanguineous populations, biallelic variants in typically dominant genes remain underrecognized. This study characterized their clinical and molecular features and explored pathway‐level patterns of dual inheritance. Exome data from 1450 individuals analyzed between 2022 and 2024 were retrospectively reviewed. Biallelic variants were filtered in genes annotated as autosomal dominant in OMIM. A pathway‐based analysis using Gene Ontology and STRING identified functionally related genes, and those showing both dominant and recessive inheritance were further evaluated with gnomAD constraint metrics to explore shared mechanisms. Five consanguineous families carried biallelic variants in genes typically associated with dominant inheritance, accounting for ~3.1% of all homozygous pathogenic variants. Mechanisms included hypomorphic effects ( TERC, ASH1L ), semidominant dosage sensitivity ( LRP5 ), structural or positional effects ( FBN1 ), and complete loss of function with pleiotropy ( SMAD6 ). Pathway analysis revealed dosage‐sensitive dynamics in telomere maintenance, extracellular matrix, Wnt/BMP signaling, and histone modification, supporting dual‐inheritance behavior driven by gene dosage and functional impact. Our findings show that genes labeled autosomal dominant can also cause disease biallelically, reflecting a dosage‐sensitive continuum. Including such analyses in diagnostic pipelines, especially in consanguineous populations, can refine understanding of inheritance in rare disorders.


  • Open Access

    Tüberoskleroz Kompleksi Tanılı Çocuk Hastalarda Everolimus Tedavisine İkincil Hiperlipidemi: Üç Olgunun Retrospektif Değerlendirmesi

    by Sevgi Doğan, Gizem Gökçe Altaş, Şule Yeşil, Deniz Yüksel, Mustafa Kılıç

    Çocuklarda hiperlipidemi primer ve sekonder kaynaklı olabilir. Primer hiperlipidemi lipid ilişkili genetik nedenlere bağlı iken, sekonder hiperlipidemi altta yatan ikincil hastalıklara ve kullanılan ilaçlara bağlı olabilir. Tüberoskleroz tedavisinde kullanılan ve mTOR inhibitörü olan Everolimus, sekonder hiperlipidemiye neden olabilmektedir. Kliniğimize son iki yıl içerisinde konsülte edilen üç hastanın Everolimus tedavisi sürecindeki kan lipid değerleri geriye dönük olarak incelendi. Klinik ve biyokimyasal bulguları araştırıldı. Everolimus tedavisi alan her üç hastada sekonder hiperlipidemi gözlendi. Bir hastanın LDL kolesterol düzeyinde, bir hastanın trigliserid, bir hastanın ise hem LDL kolesterol, hem de trigliserid düzeylerinde yükselme oldu. Everolimus doz azaltımı ya da ara verilmesi ve yağdan kısıtlı diyet ile düzelme gözlendi. Bu durumda ilaç doz azaltımı, ara verilmesi ya da yağdan kısıtlı diyet ve antihiperlipidemik ilaçlar kullanılabilir. Primer hastalığın evresi ve plazma lipid düzeyleri tedavi kararında belirleyici rol oynar.

  • A comparative analysis of all reported patients with MTHFS-related neurodevelopmental disorder

    by Mustafa Kılıç, Suzan İcIl, Esra Sayar, Sevgi Doğan, Gizem Gökçe-Altaş, Elif Güler, Abdullah Sezer

    Objectives: 5,10-Methenyltetrahydrofolate synthetase (MTHFS) deficiency is an ultra-rare autosomal recessive inborn error of folate metabolism caused by biallelic pathogenic variants in the MTHFS gene and associated with a severe neurodevelopmental disorder. Methods: Patients with molecularly confirmed MTHFS deficiency were identified through a comprehensive search of the PubMed database. A total of 12 patients from 10 unrelated families, including our patient, were analyzed. Demographic data, clinical features, biochemical findings, neuroimaging and electrophysiological results, molecular genetic characteristics, treatment responses, and outcomes were systematically compared. Results: The disorder showed a pan-ethnic distribution. All patients presented with symptoms during the neonatal and/or infantile period. Clinical features included severe global developmental delay, microcephaly, hypotonia, growth retardation, mild dysmorphic features, and epilepsy. The male-to-female ratio was 1:1, and parental consanguinity was reported in 30 % of families. Laboratory findings revealed macrocytic anemia, hyperhomocysteinemia, and mildly reduced or low–normal cerebrospinal fluid 5-methyltetrahydrofolate levels. Brain magnetic resonance imaging demonstrated cerebral hypomyelination, thinning of the corpus callosum, cerebellar atrophy, vermian hypoplasia, and T2 hypointensity of the basal ganglia. Homozygous variants were identified in 60 % of patients, and missense variants accounted for 50 % of all detected variants. A total of 12 distinct pathogenic variants were reported, with c.434G>A p.(Arg145Gln) being the most recurrent (4/20 alleles, 20 %). Despite metabolic treatment, no significant clinical improvement was observed. Two patients (17 %) died at an early age, while the remaining patients exhibited severe neurodevelopmental impairment. Conclusions: MTHFS deficiency should be considered in the differential diagnosis of patients presenting with severe developmental delay and microcephaly accompanied by isolated hyperhomocysteinemia.

  • Open Access

    Uses of miRNAs in Pediatric Diseases

    by Harun Bayrak, Harun Yıldız, Parisa Sharafi, Mustafa Kılıç

    The expression of protein-coding genes is regulated by microRNAs (miRNAs), which are small non-coding RNAs typically 18-24 nucleotides in size. miRNAs have been found to play a critical role in regulating biological functions such as proliferation, differentiation, and development. MicroRNAs are transcribed by RNA polymerase II in the genome, and mature miRNAs bind to their target mRNA in the cytoplasm, thereby inhibiting translation. MicroRNAs are potential biomarkers for diseases and alternative therapeutic agents. A noninvasive test method with a low false-negative rate is required for the diagnosis of diseases in children. Along with discussing their potential use as biomarkers in pediatric diseases, this study aims to comprehensively examine miRNA research. The aim of this review is to emphasize that miRNAs can also serve as biomarkers and alternative therapeutic agents for pediatric diseases and to raise awareness.

  • Open Access

    Novel FUCA1 variants in two families, including the first report of a contiguous gene deletion syndrome involving FUCA1 and HMGCL

    by Mustafa Kılıç, Harun Yıldız, Firdevs Dinçsoy Bir

    Background: Fucosidosis is a rare, autosomal recessive lysosomal storage disorder caused by deficiency of an alpha-L-fucosidase due to pathogenic variants in the FUCA1 gene, leading to the accumulation of fucoglyco-conjugates in the lysosomes of the liver, brain, skin and other organs. Its main clinical features include progressive neurological deterioration, seizures, coarse facies, visceromegaly, angiokeratoma, growth retardation, recurrent sinopulmonary infections and dysostosis multiplex. Case Presentation. Three patients with fucosidosis from two unrelated families with severe developmental delay, hearing loss, coarse facies but no hepatosplenomegaly and angiokeratoma are presented. A homozygous, novel nonsense mutation c.236G>A (p.Trp79*) in exon 1 of the FUCA1 gene was identified in one family, and a homozygous novel 64.5 kb deletion, including HMGCL (exons 1-6), FUCA1, and CNR2 (exon 2) genes in the other. Conclusions: Fucosidosis should be considered in patients with delayed motor and cognitive development followed by progressive neurological deterioration, even in the absence of common features such as organomegaly and angiokeratoma. The pathogenic variants identified in both families were novel and consistent with fucosidosis type 1. To our knowledge, this is the first reported case of fucosidosis accompanied by 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) lyase deficiency resulting from a contiguous gene deletion involving the HMGCL gene at the 1p36.11 locus.